Journal article
Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR plus breast cancer in the SOFT trial
Ruth O'Regan, Yi Zhang, Gini F Fleming, Prudence Francis, Roswitha Kammler, Giuseppe Viale, Istvan Lang, Meritxell Bellet Ezquerra, Herve R Bonnefoi, Sherene Loi, Marco Colleoni, Catherine A Schnabel, Kai Treuner, Meredith Regan
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2023
Abstract
Abstract Background: The landmark Suppression of Ovarian Function Trial (SOFT) in premenopausal breast cancer patients revealed that the addition of ovarian function suppression (OFS) to adjuvant endocrine therapy with either tamoxifen (T+OFS) or exemestane (E+OFS) reduces the risk of recurrence compared with adjuvant tamoxifen alone. The benefit from the addition of OFS was most clinically meaningful for patients at higher clinico-pathologic risk of recurrence. There are no biomarkers to aid decision-making about intensification of endocrine therapy with OFS and its resultant toxicities. The Breast Cancer Index (BCI) is a gene expression–based signature that stratifies patien..
View full abstract